Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

1-25 of 191 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2 3 Next ...

Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.
Smithy JW, Kalvin HL, Ehrich FD, Shah R, Adamow M, Raber V, Maher CA, Kleman J, McIntyre DAG, Shoushtari AN, Betof Warner A, Callahan MK, Momtaz P, Eton O, Nair S, Wolchok JD, Chapman PB, Berger MF, Panageas KS, Postow MA
Clin Cancer Res, 30(16):3407-3415, 01 Aug 2024
Cited by: 0 articles | PMID: 38767650
Add to export list
A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.
Barker CA, D'Angelo SP, Wasilewski G, Steckler AM, Lian M, Zhang Z, Chapman PB, Shoushtari AN, Ariyan CE
Radiother Oncol, 200:110478, 17 Aug 2024
Cited by: 0 articles | PMID: 39159678
Add to export list
A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease.
Smithy JW, Chapman PB
Cancer J, 30(2):48-53, 01 Mar 2024
Cited by: 0 articles | PMID: 38527257
Add to export list Review
Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib.
Chapman PB, Klang M, Postow MA, Shoushtari AN, Sullivan RJ, Wolchok JD, Merghoub T, Budhu S, Wong P, Callahan MK, Zheng B, Zippin J
Cancer Res Commun, 3(12):2447-2454, 01 Dec 2023
Cited by: 1 article | PMID: 37930123 | PMCID: PMC10695100
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy.
Atkinson TM, Hay JL, Young Kim S, Schofield E, Postow MA, Momtaz P, Warner AB, Shoushtari AN, Callahan MK, Wolchok JD, Li Y, Chapman PB
Oncologist, 28(4):351-357, 01 Apr 2023
Cited by: 4 articles | PMID: 36745014 | PMCID: PMC10078893
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1.
Loo K, Kalvin HL, Panageas KS, Callahan MK, Chapman PB, Momtaz P, Shoushtari AN, Wolchok JD, Postow MA, Warner AB
Pigment Cell Melanoma Res, 36(3-4):314-320, 11 Apr 2023
Cited by: 1 article | PMID: 37039320
Add to export list
PD-1 or PD-L1 Blockade Adds Little to Combination of BRAF and MEK Inhibition in the Treatment of BRAF V600-Mutated Melanoma.
Callahan MK, Chapman PB
J Clin Oncol, 40(13):1393-1395, 14 Jan 2022
Cited by: 4 articles | PMID: 35030031 | PMCID: PMC9061142
Add to export list Free full text in Europe PMC
Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).
Postow MA, Goldman DA, Shoushtari AN, Betof Warner A, Callahan MK, Momtaz P, Smithy JW, Naito E, Cugliari MK, Raber V, Eton O, Nair SG, Panageas KS, Wolchok JD, Chapman PB
J Clin Oncol, 40(10):1059-1067, 20 Dec 2021
Cited by: 27 articles | PMID: 34928709 | PMCID: PMC8966970
Add to export list Free full text in Europe PMC
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
Chapman PB, Jayaprakasam VS, Panageas KS, Callahan M, Postow MA, Shoushtari AN, Wolchok JD, Betof Warner A
J Immunother Cancer, 9(10):e003395, 01 Oct 2021
Cited by: 6 articles | PMID: 34702752 | PMCID: PMC8549669
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes.
Chapman PB
J Clin Oncol, 39(24):2640-2642, 04 Jun 2021
Cited by: 5 articles | PMID: 34086482 | PMCID: PMC8376378
Add to export list Free full text in Europe PMC
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade.
Shen R, Postow MA, Adamow M, Arora A, Hannum M, Maher C, Wong P, Curran MA, Hollmann TJ, Jia L, Al-Ahmadie H, Keegan N, Funt SA, Iyer G, Rosenberg JE, Bajorin DF, Chapman PB, Shoushtari AN, Betof AS, [...] Callahan MK
Sci Transl Med, 13(608):eabf5107, 01 Aug 2021
Cited by: 49 articles | PMID: 34433638 | PMCID: PMC9254663
Add to export list Free full text in Europe PMC
The State of Melanoma: Emergent Challenges and Opportunities.
Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, [...] Melanoma Research Foundation
Clin Cancer Res, 27(10):2678-2697, 07 Jan 2021
Cited by: 38 articles | PMID: 33414132 | PMCID: PMC8127340
Add to export list Free full text in Europe PMC
Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas.
Shoushtari AN, Chatila WK, Arora A, Sanchez-Vega F, Kantheti HS, Rojas Zamalloa JA, Krieger P, Callahan MK, Betof Warner A, Postow MA, Momtaz P, Nair S, Ariyan CE, Barker CA, Brady MS, Coit DG, Rosen N, Chapman PB, Busam KJ, [...] Schultz N
Clin Cancer Res, 27(8):2226-2235, 28 Jan 2021
Cited by: 21 articles | PMID: 33509808 | PMCID: PMC8046739
Add to export list Free full text in Europe PMC
The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas.
Makohon-Moore AP, Lipson EJ, Hooper JE, Zucker A, Hong J, Bielski CM, Hayashi A, Tokheim C, Baez P, Kappagantula R, Kohutek Z, Makarov V, Riaz N, Postow MA, Chapman PB, Karchin R, Socci ND, Solit DB, Chan TA, [...] Iacobuzio-Donahue CA
Clin Cancer Res, 27(5):1516-1525, 15 Dec 2020
Cited by: 5 articles | PMID: 33323400 | PMCID: PMC7925434
Add to export list Free full text in Europe PMC
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).
Hodi FS, Chapman PB, Sznol M, Lao CD, Gonzalez R, Smylie M, Daniels GA, Thompson JA, Kudchadkar R, Sharfman W, Atkins M, Spigel DR, Pavlick A, Monzon J, Kim KB, Ernst S, Khushalani NI, van Dijck W, Lobo M, Hogg D
Melanoma Res, 31(1):67-75, 01 Feb 2021
Cited by: 11 articles | PMID: 33234846 | PMCID: PMC7757740
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia.
Smithy JW, Pianko MJ, Maher C, Postow MA, Shoushtari AN, Momtaz P, Chapman PB, Wolchok JD, Park JH, Callahan MK
J Immunother, 44(1):9-15, 01 Jan 2021
Cited by: 5 articles | PMID: 33290361 | PMCID: PMC7727280
Add to export list Free full text in Europe PMC
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.
Postow MA, Knox SJ, Goldman DA, Elhanati Y, Mavinkurve V, Wong P, Halpenny D, Reddy SK, Vado K, McCabe D, Ramirez KA, Macri M, Schwarzenberger P, Ricciardi T, Ryan A, Venhaus R, Momtaz P, Shoushtari AN, Callahan MK, [...] Barker CA
Clin Cancer Res, 26(13):3193-3201, 23 Mar 2020
Cited by: 19 articles | PMID: 32205463 | PMCID: PMC7959513
Add to export list Free full text in Europe PMC
Immune Checkpoint Inhibitor-Associated Optic Neuritis.
Francis JH, Jaben K, Santomasso BD, Canestraro J, Abramson DH, Chapman PB, Berkenstock M, Aronow ME
Ophthalmology, 127(11):1585-1589, 08 May 2020
Cited by: 16 articles | PMID: 32437864 | PMCID: PMC8488949
Add to export list Free full text in Europe PMC
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
Hauschild A, Ascierto PA, Schadendorf D, Grob JJ, Ribas A, Kiecker F, Dutriaux C, Demidov LV, Lebbé C, Rutkowski P, Blank CU, Gutzmer R, Millward M, Kefford R, Haas T, D'Amelio A, Gasal E, Mookerjee B, Chapman PB
Eur J Cancer, 125:114-120, 01 Jan 2020
Cited by: 33 articles | PMID: 31864178 | PMCID: PMC8073226
Add to export list Free full text in Europe PMC
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.
Betof Warner A, Palmer JS, Shoushtari AN, Goldman DA, Panageas KS, Hayes SA, Bajwa R, Momtaz P, Callahan MK, Wolchok JD, Postow MA, Chapman PB
J Clin Oncol, 38(15):1655-1663, 13 Feb 2020
Cited by: 95 articles | PMID: 32053428 | PMCID: PMC7238490
Add to export list Free full text in Europe PMC
Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
Bello DM, Panageas KS, Hollmann T, Shoushtari AN, Momtaz P, Chapman PB, Postow MA, Callahan MK, Wolchok JD, Brady MS, Coit DG, Ariyan CE
Ann Surg Oncol, 27(4):1180-1188, 17 Dec 2019
Cited by: 24 articles | PMID: 31848819 | PMCID: PMC7112166
Add to export list Free full text in Europe PMC
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF ^V600-mutated Metastatic Melanoma.
Yan Y, Wongchenko MJ, Robert C, Larkin J, Ascierto PA, Dréno B, Maio M, Garbe C, Chapman PB, Sosman JA, Shi Z, Koeppen H, Hsu JJ, Chang I, Caro I, Rooney I, McArthur GA, Ribas A
Clin Cancer Res, 25(11):3239-3246, 01 Mar 2019
Cited by: 21 articles | PMID: 30824584 | PMCID: PMC8083896
Add to export list Free full text in Europe PMC
Treatment Outcomes of Immune-Related Cutaneous Adverse Events.
Phillips GS, Wu J, Hellmann MD, Postow MA, Rizvi NA, Freites-Martinez A, Chan D, Dusza S, Motzer RJ, Rosenberg JE, Callahan MK, Chapman PB, Geskin L, Lopez AT, Reed VA, Fabbrocini G, Annunziata MC, Kukoyi O, Pabani A, [...] Lacouture ME
J Clin Oncol, 37(30):2746-2758, 19 Jun 2019
Cited by: 97 articles | PMID: 31216228 | PMCID: PMC7001790
Add to export list Free full text in Europe PMC
Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience.
Lee Chuy K, Oikonomou EK, Postow MA, Callahan MK, Chapman PB, Shoushtari AN, Neilan TG, Fradley MG, Ramanathan LV, Wolchok JD, Steingart RM, Gupta D
Oncologist, 24(5):e196-e197, 25 Mar 2019
Cited by: 20 articles | PMID: 30910868 | PMCID: PMC6516118
Add to export list Free full text in Europe PMC
Intermittent Treatment With MEK Inhibitors in Patients With Oncogenic RAF-Driven Tumors: A Potential Strategy to Manage Toxicity and Maintain Efficacy.
Yaeger R, Yao Z, Chapman PB
JCO Precis Oncol, 2:1-2, 01 Nov 2018
Cited by: 1 article | PMID: 35135118
Add to export list

1-25 of 191 results

1 2 3 Next ...

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.

A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.

A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease.

Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib.

Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy.

Beyond the 5-year milestone: Long-term survivorship of melanoma patients treated off-trial with anti-PD-1.

PD-1 or PD-L1 Blockade Adds Little to Combination of BRAF and MEK Inhibition in the Treatment of BRAF V600-Mutated Melanoma.

Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study).

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.

Targeting Tumor-Rejection Antigens in Melanoma With Tumor-Infiltrating Lymphocytes.

LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade.

The State of Melanoma: Emergent Challenges and Opportunities.

Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas.

The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas.

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).

Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia.

A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.

Immune Checkpoint Inhibitor-Associated Optic Neuritis.

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.

Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.

Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF ^V600-mutated Metastatic Melanoma.

Treatment Outcomes of Immune-Related Cutaneous Adverse Events.

Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience.

Intermittent Treatment With MEK Inhibitors in Patients With Oncogenic RAF-Driven Tumors: A Potential Strategy to Manage Toxicity and Maintain Efficacy.

Partnerships & funding